Measles outbreak in Brazil, 2018

Measles infection is caused by a single-stranded, negative-strand RNA respiratory virus of the family Paramyxoviridae and genus Morbillivirus. Measles virus is a highly contagious acute febrile disease associated with a characteristic erythematous, maculopapular rash. Considered one of the most communicable illnesses, measles is transmitted by airborne droplets or via direct contact with secretions from the nose, mouth, and throat of infected individuals. Measles was a leading global cause of child morbidity and mortality and responsible for more than 2 million deaths annually before the increase in global measles vaccine coverage in the 1980s. Outbreaks can occur in populations where fewer than 10% of people are not immune to the measles virus.

Measles was declared eliminated from the Americas in 2016, following the declaration of rubella and congenital rubella syndrome elimination in 2015. During 2017 and 2018, there have been many countries in the Americas Region reporting confirmed cases of measles including Antigua and Barbuda, Brazil, Canada, Guatemala, Mexico, Peru, United States, Venezuela and Argentina. Venezuela’s ongoing health crisis accounted for the majority of reported cases. In Brazil, there is an ongoing measles outbreak. From January to November 2018, there were 2,801 confirmed measles cases in Brazil. The vast majority of cases were reported in Amazonas (2,357 cases) and Roraima (345 cases) States in northern Brazil. Indigenous populations living close to the Venezuelan borders are particularly vulnerable to measles outbreaks. There were 77 confirmed cases among indigenous Yanomami and Ye’kuna communities in Roraima and Amazonas states, according to Pan American Health Organization.

Immunization has proven to be one of public health’s most cost-effective interventions. Measles surveillance and increase global coverage with two doses of measles vaccine through substantial and sustained additional investments in health systems are urgent efforts to achieve the regional elimination goals. Additional evaluation of the cost of two-dose schedules and its serological can provide valuable information for eventual global eradication.

REFERENCES


Luciano Z. Goldani*
Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Unidade de Doenças Infecciosas, Porto Alegre, RS, Brazil
E-mail address: lgoldani@ufrgs.br
1413-8670/Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Infectologia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.bjid.2018.11.001